免疫功能低下重症患者巨细胞病毒终末器官病的临床特征与结局:多中心回顾性队列研究
该多中心国际回顾性观察研究纳入法国、以色列和西班牙18个ICU的185例成人CMV终末器官病患者(排除AIDS),最常见为肺炎(62.2%)和胃肠道病(34.6%),院内死亡率61.4%。血液系统恶性肿瘤组死亡率显著高于其他组(75% vs 51%,P=0.001)。多因素分析显示,伴活动性移植物抗宿主病的血液系统恶性肿瘤、CMV肺炎、诊断时淋巴细胞<0.30×10^9/L、入ICU时SOFA评分更高及年龄更大与院内死亡独立相关。CMV肺炎很少经组织病理学证实,但为最严重的CMV终末器官病。
要点
- 185例免疫功能低下CMV终末器官病重症患者院内死亡率为61.4%。
- 血液系统恶性肿瘤患者院内死亡率显著高于其他患者(75% vs 51%,P=0.001)。
- CMV肺炎最常见(62.2%),但仅8.7%经组织病理学证实,且为最严重类型。
- 独立死亡危险因素:伴活动性GVHD的血液系统恶性肿瘤(OR 5.02)、CMV肺炎(OR 2.57)、淋巴细胞<0.30×10^9/L(OR 2.40)、SOFA评分高(OR 1.18)、年龄大(OR 1.04)。
适用人群与场景
- 2010年1月至2021年12月入住法国、以色列和西班牙18个ICU的成人CMV终末器官病患者。
- 排除AIDS患者。
- 基础免疫缺陷包括:血液系统恶性肿瘤80例(43.2%)、实体器官移植55例(29.7%)、使用免疫抑制剂31例(16.8%)、实体恶性肿瘤16例(8.6%)、原发性免疫缺陷3例(1.6%)。
红旗征与不能漏的情况
- CMV肺炎为最严重的CMV终末器官病,且很少经组织病理学证实(10/115,8.7%)。
研究设计与关键结果
- 多中心、国际、回顾性、观察性研究,纳入185例成人CMV终末器官病患者。
- CMV终末器官病类型:肺炎115例(62.2%,其中55例[47.8%]合并呼吸道共病原体)、胃肠道病64例(34.6%)、超过一个器官受累16例(8.8%)。
- 组织病理学证据:肺炎10/115(8.7%),胃肠道病43/64(67.2%)。
- 其他机会性感染69例(37.3%)。
- 院内死亡率61.4%,血液系统恶性肿瘤组显著高于其他组(75% vs 51%,P=0.001)。
- 独立危险因素:伴活动性移植物抗宿主病的血液系统恶性肿瘤(OR 5.02;95% CI 1.15-27.30)、CMV肺炎(OR 2.57;95% CI 1.13-6.03)、诊断CMV终末器官病时淋巴细胞<0.30×10^9/L(OR 2.40;95% CI 1.05-5.69)、入ICU时SOFA评分更高(OR 1.18;95% CI 1.04-1.35)、年龄更大(OR 1.04;95% CI 1.01-1.07)。
证据类型、等级与局限
- 证据类型:多中心、国际、回顾性、观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于免疫功能低下(如血液系统恶性肿瘤、实体器官移植、使用免疫抑制剂)的危重患者,出现CMV终末器官病时院内死亡风险高(61.4%),尤其血液系统恶性肿瘤患者(75% vs 51%,P=0.001)。
- CMV肺炎虽常见(62.2%)但组织病理学证实率低(8.7%),临床上需警惕其严重性(OR 2.57)。
- 诊断CMV终末器官器官病时淋巴细胞<0.30×10^9/L(OR 2.40)、入ICU时SOFA评分更高(OR 1.18)及年龄更大(OR 1.04)与更高院内死亡风险独立相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cytomegalovirus (CMV) infection in patients with cellular immune deficiencies is associated with significant morbidity and mortality. However, data on CMV end-organ disease (CMV-EOD) in critically ill, immunocompromised patients are scarce. Our objective here was to describe the clinical characteristics and outcomes of CMV-EOD in this population.
METHODS: We conducted a multicenter, international, retrospective, observational study in adults who had CMV-EOD and were admitted to any of 18 intensive care units (ICUs) in France, Israel, and Spain in January 2010-December 2021. Patients with AIDS were excluded. We collected the clinical characteristics and outcomes of each patient. Survivors and non-survivors were compared, and multivariate analysis was performed to identify risk factors for hospital mortality.
RESULTS: We studied 185 patients, including 80 (43.2%) with hematologic malignancies, 55 (29.7%) with solid organ transplantation, 31 (16.8%) on immunosuppressants, 16 (8.6%) with solid malignancies, and 3 (1.6%) with primary immunodeficiencies. The most common CMV-EOD was pneumonia (n = 115, [62.2%] including 55 [47.8%] with a respiratory co-pathogen), followed by CMV gastrointestinal disease (n = 64 [34.6%]). More than one organ was involved in 16 (8.8%) patients. Histopathological evidence was obtained for 10/115 (8.7%) patients with pneumonia and 43/64 (67.2%) with GI disease. Other opportunistic infections were diagnosed in 69 (37.3%) patients. Hospital mortality was 61.4% overall and was significantly higher in the group with hematologic malignancies (75% vs. 51%, P = 0.001). Factors independently associated with higher hospital mortality were hematologic malignancy with active graft-versus-host disease (OR 5.02; 95% CI 1.15-27.30), CMV pneumonia (OR 2.57; 95% CI 1.13-6.03), lymphocytes < 0.30 × 109/L at diagnosis of CMV-EOD (OR 2.40; 95% CI 1.05-5.69), worse SOFA score at ICU admission (OR 1.18; 95% CI 1.04-1.35), and older age (OR 1.04; 95% CI 1.01-1.07).
CONCLUSIONS: Mortality was high in critically ill, immunocompromised patients with CMV-EOD and varied considerably with the cause of immunodeficiency and organ involved by CMV. Three of the four independent risk factors identified here are also known to be associated with higher mortality in the absence of CMV-EOD. CMV pneumonia was rarely proven by histopathology and was the most severe CMV-EOD.
参考来源
- Fernández S, Grafia I, Peyrony O, et al. Clinical characteristics and outcomes of immunocompromised critically ill patients with cytomegalovirus end-organ disease: a multicenter retrospective cohort study. Crit Care. 2024. PMID: 39014504. doi:10.1186/s13054-024-05029-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。